Landry, who was 69, succumbed to complications from lung cancer, a spokesman says. He is survived by his wife of 46 years, Barrie, as well as his three children and nine grandchildren.
Landry spent his entire professional career at TA, according to a memorial on the firm’s web site. He became a TA general partner in 1972, a managing partner in 1982 and CEO in 1984. In 2007, he was named chairman and remained actively involved until his retirement in 2012. He served as a TA senior advisor until his death.
Landry was an early backer of companies including biotechnology firm Biogen (now Biogen Idec) and Continental Cablevision, the Boston Globe said. The executive often went against the tide, allowing TA partners to do Internet deals only briefly during the dot.com bubble, the story says.
Landry was considered a pioneer in the PE industry. He maintained a conservative investment culture at TA Associates, while other private-equity firms, such as Blackstone Group LP , have been criticized for using too much leverage in their takeovers, Reuters has reported. Landry was also a licensed pilot and would fly his own jet to meet prospective investment targets.
He was instrumental in TA’s evolution from a regional venture capital investor to a growth private equity firm, the firm’s memorial says. “Kevin embodied an ethos of doing the right thing for our investors. On several occasions, for example, he directed the firm to voluntarily make fee and other concessions to our limited partners because ‘it was the right thing to do,'” TA said.
Partners at TA Associates recently made a $10 million gift to Harvard University to endow the Landry Cancer Biology Consortium and the Landry Cancer Research fellowships. The $10 million gift will fund research on cancer biology and treatments, including lung cancer studies, the memorial says.
Photo courtesy of TA Associates
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.